Medicine and Dentistry
Prostate Cancer
100%
Bladder Cancer
49%
Prostatectomy
39%
Cystectomy
36%
Neoplasm
30%
Lymph Node
29%
Transitional Cell Carcinoma
27%
Prostate Specific Membrane Antigen
22%
Retroperitoneal Lymph Node Dissection
18%
Diseases
18%
Bladder
17%
Malignant Neoplasm
17%
Positron Emission Tomography
17%
Radiation Therapy
15%
Recurrent Disease
15%
Metastatic Carcinoma
14%
Prostate Specific Antigen
14%
Gallium 68
14%
Lymph Node Metastasis
12%
Pelvis
12%
Immunotherapy
12%
Systemic Therapy
12%
Positron Emission Tomography-Computed Tomography
11%
Polyethylene Terephthalate
11%
Urothelial Cancer
11%
Neobladder
10%
Overall Survival
9%
Kidney Metastasis
9%
Urology
9%
Computer Assisted Tomography
9%
Muscle Invasive Bladder Cancer
9%
Radiosurgery
9%
Carbon 11
8%
Family History
8%
Choline
8%
Biopsy Technique
8%
Magnetic Resonance Imaging
7%
Oncology
7%
Biochemical Recurrence
7%
Quality of Life
7%
Clear Cell Renal Cell Carcinoma
7%
Urologist
7%
Castration Resistant Prostate Cancer
6%
Clinical Trial
6%
Sunitinib
6%
Cancer Cell
6%
Nivolumab
6%
Survival Rate
6%
Urinary Diversion
5%
Immune Checkpoint Inhibitor
5%
Keyphrases
Prostate Cancer
61%
Bladder Cancer
43%
Radical Prostatectomy
39%
Prostate-specific Antigen
34%
Radical Cystectomy
28%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
20%
Metastatic Renal Cell Carcinoma (mRCC)
19%
Prostate Cancer Patients
18%
Tumor
17%
Overall Survival
14%
Chemotherapy
14%
Lymph Node Metastasis
13%
Germany
13%
Recurrent Prostate Cancer
13%
Lymph Node
12%
Cystectomy
11%
Sunitinib
11%
Positron Emission Tomography
10%
High Risk
10%
Cancer Patients
10%
Upper Tract Urothelial Carcinoma
10%
Renal Cell Carcinoma
9%
Confidence Interval
9%
Urothelial Cancer
9%
Everolimus
9%
Muscle-invasive Bladder Cancer
9%
Urology
9%
Docetaxel
8%
Radioguided Surgery
8%
Biochemical Recurrence-free Survival
8%
Pazopanib
8%
Nivolumab
8%
Family History
7%
Systemic Therapy
7%
Prostate
7%
Metastasis
7%
Invasive Urothelial Carcinoma
7%
Castration-resistant Prostate Cancer
7%
Phase II Trial
7%
Bone Metastasis
7%
Salvage Radiotherapy
7%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Prednisone
7%
Urothelial Carcinoma
7%
Prostate Cancer Survivors
7%
Urologists
7%
Biochemical Recurrence
6%
Apoptosis
6%
Clinical Trials
6%
Immune Checkpoint Inhibitors
6%